The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.
Vertex Pharmaceuticals has recently achieved two significant FDA approvals in just 41 days. On December 20, 2024, the FDA approved Alyftrek for treating cystic fibrosis (CF), followed by the approval of Journavx, a novel treatment for moderate-to-severe acute pain, just a few days later.
The FDA has granted approval for Roche’s PATHWAY HER2 (4B5) test to identify HER2-ultralow status in metastatic breast cancer patients, expanding its existing use for detecting HER2-low cases. This approval follows AstraZeneca and Daiichi Sankyo’s recent FDA clearance for Enhertu (trastuzumab deruxtecan) in HER2-ultralow patients, marking a significant advancement in breast cancer treatment. Enhertu is the first HER2-targeting antibody-drug conjugate (ADC) approved for patients with an immunohistochemistry (IHC) score of zero with faint staining in 10% or fewer tumor cells.
This systematic review and meta-analysis assessed the burden of micronutrient deficiencies among patients with type 2 diabetes (T2D), analyzing 132 studies with 52,501 participants. Micronutrient deficiencies in T2D were 45.30%, with vitamin D (60.45%), magnesium (41.95%), and B12 (28.72%) most common. Women were more affected.
The study provides a comprehensive analysis of diabetes trends among adolescents aged 10–24 years. Using data from the Global Burden of Disease (GBD) 2021 study, it estimates the prevalence, disability-adjusted life years (DALYs), and risk factors for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) across 204 countries and territories. The findings reveal a significant increase in the global burden of adolescent diabetes, with 3.4 million living with T1DM and 14.6 million with T2DM in 2021. By 2030, these numbers are projected to rise to 3.7 million and 20.9 million, respectively.
